Two gene therapy biotech firms are taking different approaches against a background of challenging markets as Freeline Therapeutics Holdings PLC divests a manufacturing-focused subsidiary to lengthen its cash runway while Kriya Therapeutics, Inc. expands into the neurology space with its acquisition of Redpin Therapeutics, Inc..
First up, Freeline is divesting its German subsidiary in a bid to streamline operations as it focuses on advancing its...
Welcome to Scrip
Create an account to read this article
Already a subscriber?